A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Phase I Study of Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic Effect of NTQ1062 Tablets in Chinese Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06172309
• Other study ID #: NTQ1062-21101
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: September 13, 2021
• Est. completion date: June 2024

Study information

• Verified date: December 2023
• Source: Nanjing Chia-tai Tianqing Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single-arm, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic effect of NTQ1062 in patients with advanced solid tumors.

The study comprises a dose-escalation phase and a dose-expansion phase.

1. Dose-escalation:using 3+3 design to evaluate the safety, tolerability, and pharmacokinetic profile of NTQ1062 at 20, 50, 100, 200, 300, 400 mg in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD).

2. Dose-expansion:the dose-expansion study will evaluate the safety, tolerability, and preliminary pharmacodynamic effect of the MTD for NTQ1062 in patients with advanced solid tumors, and to identify the recommended phase 2 dose (RP2D).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 32
• Est. completion date: June 2024
• Est. primary completion date: April 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Aged at least 18 years old, male or female patients.

2. Patients with histologically and cytologically confirmed, advanced malignant solid tumors who have progressed on standard therapy or for whom no standard therapy exists, or for whom no standard treatment is available.

3. (Dose escalation phase)Solid tumors that are at least one evaluable per Response Evaluation Criteria in Solid Tumors(RECIST v1.1);(Dose expansion phase)Solid tumors that are at least one measurable per Response Evaluation Criteria in Solid Tumors(RECIST v1.1).

4. ECOG score is 0-1.

5. Predicted life expectancy =3 months.

6. Patients must have adequate organ function:

1. Absolute neutrophil count (ANC) = 1.5×109/L, platelet count = 75×109/L, hemoglobin = 85 g/L.

2. Liver function: Total bilirubin = 1.5xULN, AST and ALT = 3.0xULN (= 5.0xULN for patients with Patients with hepatic metastases or hepatic carcinoma).

3. Renal function:Creatinine (Cr) = 1.5xULN or creatinine clearance (Ccr) = 50 ml/min/1.73m2.

4. Coagulation function: activated partial thromboplastin time (APTT) and INR =1.5×ULN.

7. Female patients of child-bearing potential, and all male partners must consent to use a acceptable method of contraception throughout the study period and for 90 days after the last dose of either study drug.

8. Patients must be signed written informed consent prior to admission to the study.

Exclusion Criteria:

1. Clinically significant abnormalities of glucose metabolism as defined by any of the following:

1. Diagnosis of diabetes mellitus type I.

2. Baseline fasting glucose value of =8.33 mmol/l (150 mg/dL).

3. Glycosylated haemoglobin (HbA1C) =8%.

2. Patients who are still receive anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy and other anti-tumor drug from 4 weeks prior to the first dose.

3. Patients have received previous treatment with a AKT,PI3K or mTOR inhibitor.

4. Patients received strong inhibitors and/or inducers of CYP3A4 within 7 days prior to the first dose of study drug.

5. Active infection requiring systemic treatment.

6. Active hepatitis B virus infection or hepatitis C virus infection.

7. History of human immunodeficiency virus infection.

8. Patient has symptomatic CNS metastases.

9. History of severe cardiovascular diseases.

10. Other conditions that the investigator considers inappropriate for participation in this clinical trial

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Neoplasms

Intervention

Drug:
• NTQ1062
tablet(s) PO

Locations

Country	Name	City	State
China	Shandong Cancer Hospital	Jinan	Shandong
China	Shanghai East hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing Chia-tai Tianqing Pharmaceutical

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	The MTD is defined as the highest dose reached for which the incidence of dose limiting toxicity (DLT) occurs in less than 1/3 of the subjects.	First treatment cycle (i.e., the first 28 days post the first dose)
Primary	Recommended phase 2 dose (RP2D)	The RP2D of NTQ1062 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data.	First treatment cycle (i.e., the first 28 days post the first dose)
Primary	Adverse events	Safety and tolerability of NTQ1062. Incidence of adverse events.	through study completion, an average of 1 year
Secondary	Pharmacokinetic parameters:Cmax	Maximum Serum Concentration (Cmax) of NTQ1062.	At the end of Cycle 1 (each cycle is 28 days)
Secondary	Pharmacokinetic parameters: Tmax	Time to Maximum Serum Concentration (Tmax) of NTQ1062.	At the end of Cycle 1 (each cycle is 28 days)
Secondary	Pharmacokinetic parameters: AUC	The area under the concentration versus time curve of NTQ1062.	At the end of Cycle 1 (each cycle is 28 days)
Secondary	Pharmacokinetic parameters:T1/2	The terminal half-life of NTQ1062.	At the end of Cycle 1 (each cycle is 28 days)
Secondary	Objective response rate (ORR)	ORR is defined as participants with confirmed complete or partial response (CR+PR) per RECIST, v1.1	through study completion, an average of 1 year
Secondary	Disease Control Rate(DCR)	DCR was defined as the proportion of patients who had an overall response of complete response (CR), partial response (PR), or stable disease (SD).	through study completion, an average of 1 year
Secondary	Duration of Response(DOR)	DOR is defined as the time between date of first response and the first occurrence. of progression or death from any cause, whichever occurs first.	through study completion, an average of 1 year
Secondary	Progression-free Survival(PFS)	PFS will be defined as the time between the first dose of any study drug and the first occurrence of progression or death from any cause.	through study completion, an average of 1 year